C-X-C motif chemokine receptor 2 (CXCR2) expression is associated with high-grade and advanced prostate cancer. LNCaP-CXCR2+ prostate cancer cells with stable expression of CXCR2 exhibited mesenchymal features and became more aggressive with elevated expression of an ECM oncoprotein EDB-FN as compared to the slow-growing parental cell line, LNCaP. MRMI of EDB-FN with a targeted contrast agent MT218 resulted in significant increase of T1-weighted contrast enhancement in LNCaP-CXCR2+ prostate tumors as compared to the LNCaP tumors in mice. The results suggest that MRMI of EDB-FN has the potential to provide non-invasive active surveillance of low-grade prostate cancer.
This abstract and the presentation materials are available to members only; a login is required.